Impact of a pre-emptive skin treatment regimen on skin toxicities of anti-epidermal growth factor receptor monoclonal antibodies: more questions than answers.
Rother
Mark
M
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D003879:Dermatologic Agents / Q000008:administration & dosage*; D003875:Drug Eruptions / Q000209:etiology / Q000517:prevention & control*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005076:Exanthema / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D000077544:Panitumumab; D011292:Premedication; D012867:Skin / Q000187:drug effects / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab